FASEB SRC on The Growth Hormone/Prolactin Family in Biology and Disease

描述(申请人提供)：“生长激素(GH)和催乳素(PRL)家族”定义了一个蛋白质家族，包括几个成员，包括生长激素(GH)、催乳素(PRL)、胎盘催乳素(PLs)和各种称为血管抑制素的蛋白分解片段。这些蛋白质处于人类病理生理学的两个主要领域的十字路口：细胞因子受体(与它们共享多种分子机制)和(神经)内分泌学(在调节、分泌、功能和病理生理水平上与其他激素的多种联系)。在这两个领域，生长激素和催乳素激素率先发现了范式，从作用机制(例如，1992年第一个已知的细胞因子和受体复合体的结构)到药物开发(2003年推出的第一个基于细胞因子核心的拮抗剂Somvert)。现已清楚，催乳素和生长激素调节新陈代谢(如β细胞质量、脂肪细胞分化、肌肉、葡萄糖稳态等)、干细胞生物学、行为(如神经发生)、癌症(多个器官)、免疫反应等。这些新功能令科学界非常兴奋，包括该领域的基础、翻译、临床和工业参与者。为了了解这些新功能的潜在机制，评估它们的实际临床影响，发现新的治疗适应症，开发有针对性的药物治疗，以及新的兴奋剂检测策略，有必要进行进一步的翻译研究。因此，迫切需要通过组织一次以这些问题为重点的定期和长期会议，召集参与这些研究领域的不断扩大的社区。为此，申请者建立了一个新的FASEB SRC，题为“生物学和疾病中的生长激素和催乳素家族”。会议将涉及多种领域，包括信号传递、用于确定生长激素和催乳素在健康和疾病中的新生理功能的新动物模型的开发、生长激素和催乳素激素调节的新功能/组织、生长激素和催乳素作用的生物组学分析以及新药靶点和临床前研究。最后，申请者将通过从将要提交的摘要中选择简短的演讲(提供您符合我们的质量标准)来确保覆盖目前未被列为完整演讲的最新新发现和相关主题。将作出重大努力来吸引年轻的调查人员(资金、简短的演讲、海报)。

DESCRIPTION (provided by applicant): The "Growth hormone (GH) and prolactin (PRL) family" defines a protein family that includes several members, including GH, PRL, placental lactogens (PLs) and various proteolytic fragments called vasoinhibins. These proteins are at the crossroads of two major fields in human pathophysiology: cytokine receptors (with whom they share multiple molecular mechanisms), and (neuro) endocrinology (multiple connections with other hormones at the regulation, secretion, functional and pathophysiology levels). In both areas, GH and PRL hormones have pioneered the discovery of paradigms, ranging from mechanisms of action (e.g., first known structure of cytokine and receptor complex in 1992) to drug development (Somavert, the first cytokine core-based antagonist launched in 2003). It is now clear that PRL and GH hormones regulate metabolism (e.g., beta cell mass, adipocyte differentiation, muscle, glucose homeostasis, etc), stem cell biology, behavior (e.g., neurogenesis), cancer (several organs), immune responses, etc. These novel functions are very exciting to the scientific community, including basic, translational, clinical and industrial actor in the field. Further translational investigations are necessary to understand the underlying mechanisms of these novel functions to evaluate their actual clinical impact discover new therapeutic indications, develop targeted drug therapy, and novel strategies of doping detection. There is therefore a critical need to gather the broadening community involved in these fields of research by organizing a regular and long-live meeting focused on these issues. To that end, the applicants have established a novel FASEB SRC entitled "The Growth Hormone and Prolactin Family in Biology and Disease". The conference will cover such diverse areas as signaling, development of novel animal models for identifying new physiological functions for GH and PRL in health and disease, new functions/tissues regulated by GH and PRL hormones, biomics profiling of GH and PRL actions and new drug targets and pre-clinical studies. Finally, the applicants will ensure coverage of the latest new findings and relevant topics not currently included as full talks by selecting short talks from abstracts that will be submitted (providing thy match our quality criteria). Major efforts to attract young investigators will be made (funding, short talks, posters).